Answers are grounded in this paper and cite their sources.
In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).
No takes yet. Share an insight, caveat, or question.
Schuster et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: